Combination therapy for relapsed or refractory T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of three drugs (zeprumetostat, azacitidine, and a liposomal form of mitoxantrone) for people with a type of lymphoma called peripheral T-cell lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help shrink or control the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lymphoma called peripheral T-cell lymphoma that has come back or not responded to at least one prior treatment.
- You are 18 years or older.
- You are able to take care of yourself (ECOG score 0-2), meaning you can be up and about more than half the day.
- You have at least one tumor that can be measured on a CT or MRI scan (at least 1.5 cm in size).
- Your blood counts, heart, kidney, and liver function are within acceptable limits as determined by lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing several new drug combinations for people with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to find new options that may work better.
This trial tests a combination of two drugs, Linperlisib and Chidamide, for people with peripheral T-cell lymphoma that has come back or not improved after at least one previous treatment. The goal is to see if this combination can help control the cancer.
This study tests a combination of three drugs (azacitidine, chidamide, and a PD-1 inhibitor) for T-cell lymphomas that have returned or stopped responding to previous treatment. The goal is to see if this combination can help shrink the cancer.
This trial tests a combination of three medicines (anti-PD-1, lenalidomide, and azacitidine) for adults with relapsed or refractory peripheral T-cell lymphoma (PTCL) that is measurable or growing. It aims to shrink lymphoma and improve control of the disease when standard treatments haven’t worked or have stopped working.
This trial tests a combination of two drugs (tislelizumab and zeprumetostat) for people whose NK/T-cell lymphoma has returned or stopped responding to previous treatment. The goal is to see if the combination works better than what has been tried before.
This trial tests a combination treatment for peripheral T-cell lymphoma, a type of blood cancer. It may help patients who cannot tolerate standard chemotherapy or whose disease has come back.
Hear when a new Peripheral T Cells Lymphoma (PTCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.